tiprankstipranks
Sartorius AG (GB:0NIQ)
LSE:0NIQ
UK Market

Sartorius (0NIQ) Earnings Dates, Call Summary & Reports

2 Followers

Earnings Data

Report Date
Apr 23, 2026
Before Open (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
1.29
Last Year’s EPS
1.22
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 03, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial outcome for 2025: solid revenue growth, strong margin expansion (group EBITDA margin 29.7%), robust BPS performance, healthy recurring/consumables momentum, successful product launches, strategic M&A and capacity expansions, and clearer deleveraging progress. However, notable challenges remain—equipment demand recovery is uneven and timing‑uncertain, LPS margins are under pressure from strategic investments and mix effects, FX and tariff headwinds persist, and cash flow/CapEx dynamics weigh on near‑term free cash flow. Management provided constructive yet deliberately wide 2026 guidance to reflect these uncertainties. Overall, positive achievements materially outweigh the negatives, while the company remains cautious about external risks.
Company Guidance
For 2026 management guided group sales growth of around 5–9% in constant currencies (including ~1 percentage point from the market acquisition and U.S. tariff surcharges), an underlying EBITDA margin slightly above 30% (with a technical ~50 basis‑point dilution from tariffs), a CapEx ratio around prior‑year levels (roughly 12–12.5%), and net debt/underlying‑EBITDA expected to fall to slightly above 3x; they flagged FX sensitivity (EUR/USD 1.20 implies ~2 percentage‑point reported‑growth headwind for the full year and ~4 points in Q1). By division, Bioprocess Solutions guidance is ~6–10% sales growth with an underlying EBITDA margin slightly above 32% (equipment expected at least stable), while Lab Products & Services is guided to ~2–6% sales growth (including ~1.5 pp from MATTEK) with an underlying EBITDA margin slightly below 21% (impacted by deliberate ACM investments, mix, FX and tariffs). Management noted the range is deliberately broad given macro and industry volatility and that large U.S. on‑shoring build‑outs were not baked into 2026 revenues.
Group Revenue Growth
Group sales increased 7.6% in constant currencies (4.7% reported) to just above EUR 3.5 billion for FY 2025, slightly ahead of upgraded guidance.
Strong Underlying Profitability Expansion
Underlying EBITDA rose 11.2% to EUR 1.052 billion, with the underlying EBITDA margin improving by 170 basis points to 29.7%, exceeding the October EBITDA target.
Bioprocess Solutions (BPS) Outperformance
BPS sales grew 9.5% in constant currencies; underlying EBITDA increased 15.2% to EUR 907 million and margin expanded by 240 basis points to 31.7%, driven by mid‑teens recurring consumable growth.
Recurring Business and Consumables Momentum
Recurring business (consumables) delivered mid‑teens growth across divisions, offsetting soft equipment demand and underpinning resilient revenue and margin performance.
Order Intake and Book-to-Bill Strength
Order intake grew faster than sales and the 12‑month rolling book‑to‑bill remained consistently above 1 through 2025; Q4 order intake was roughly on par with an exceptionally strong Q4 2024, leaving a strong starting order book for 2026.
Cash/Balance Sheet Improvements and Deleveraging Progress
Gross debt was reduced by EUR 277 million, net debt remained largely unchanged, and the group's leverage (net debt/underlying EBITDA) improved from 3.96x to 3.55x, with an equity ratio of 39.8%.
Strategic Innovation, M&A and Capacity Investments
Launched sustainability- and performance-focused products (Sartopore Evo, Sartocon cassettes, Pionic Continuous platform), acquired MATTEK to expand 3D cell-model capabilities, partnered with Nanotein, completed Aubagne expansion and progressed Germany and Songdo (Korea) capacity investments.
Positive 2026 Guidance
Management provided 2026 guidance calling for group sales growth of ~5%–9% (constant currencies) and an underlying EBITDA margin slightly above 30%, with BPS guidance of ~6%–10% growth and margin slightly above 32%.

Sartorius (GB:0NIQ) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

GB:0NIQ Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 23, 2026
2026 (Q1)
1.29 / -
1.22
Feb 03, 2026
2025 (Q4)
1.31 / 1.26
1.0520.00% (+0.21)
Oct 16, 2025
2025 (Q3)
1.07 / 1.08
0.21416.67% (+0.88)
Jul 22, 2025
2025 (Q2)
1.30 / 1.22
0.34258.82% (+0.88)
Apr 16, 2025
2025 (Q1)
1.18 / 1.22
1.0120.79% (+0.21)
Jan 28, 2025
2024 (Q4)
1.13 / 1.05
0.9411.70% (+0.11)
Oct 17, 2024
2024 (Q3)
0.86 / 0.21
0.1361.54% (+0.08)
Jul 18, 2024
2024 (Q2)
0.98 / 0.34
1.39-75.54% (-1.05)
Apr 18, 2024
2024 (Q1)
1.10 / 1.01
1.69-40.24% (-0.68)
Jan 26, 2024
2023 (Q4)
0.93 / 0.94
2.25-58.22% (-1.31)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GB:0NIQ Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 03, 2026
€186.80€194.56+4.16%
Oct 16, 2025
€171.26€184.41+7.67%
Jul 22, 2025
€165.49€157.72-4.69%
Apr 16, 2025
€159.51€174.85+9.61%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Sartorius AG (GB:0NIQ) report earnings?
Sartorius AG (GB:0NIQ) is schdueled to report earning on Apr 23, 2026, Before Open (Confirmed).
    What is Sartorius AG (GB:0NIQ) earnings time?
    Sartorius AG (GB:0NIQ) earnings time is at Apr 23, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Sartorius AG stock?
          The P/E ratio of Sartorius is N/A.
            What is GB:0NIQ EPS forecast?
            GB:0NIQ EPS forecast for the fiscal quarter 2026 (Q1) is 1.29.